One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...